top of page
Search

Rheumatoid Arthritis: Criteria & DMARDs — The Ultimate List (MRCP Part 1)

TL;DR

For MRCP Part 1, rheumatoid arthritis (RA) is examined through the 2010 ACR/EULAR classification criteria, serology interpretation, and rational DMARD escalation. Methotrexate is first-line unless contraindicated, biologics require TB screening, and extra-articular disease is frequently tested. This guide distils Rheumatoid Arthritis: Criteria & DMARDs: The Ultimate List (MRCP Part 1) into high-yield exam essentials.


Why this matters

Rheumatoid arthritis remains one of the most examinable rheumatology conditions in MRCP Part 1. It integrates:

  • Immunology

  • Clinical medicine

  • Pharmacology

  • Interpretation of laboratory data

The MRCP(UK) blueprint consistently includes inflammatory arthritis and autoimmune disease. RA questions often test subtle distinctions—particularly drug sequencing and adverse effects.

If you are working through the structured MRCP Part 1 overview, RA is a core topic that demands precise recall rather than broad reading.


Scope of What MRCP Part 1 Tests in RA

Expect questions on:

  1. 2010 ACR/EULAR classification criteria

  2. Anti-CCP vs rheumatoid factor

  3. Methotrexate dosing and monitoring

  4. Biologic indications and screening

  5. Extra-articular complications

  6. Radiographic findings

  7. Drug toxicities

  8. Differentiation from osteoarthritis and psoriatic arthritis


1. The 2010 ACR/EULAR Classification Criteria (High Yield)

The 2010 criteria (developed by the American College of Rheumatology and the European League Against Rheumatism) classify RA when a patient scores ≥6/10.

Domain

Points

Joint involvement

0–5

Serology (RF / anti-CCP)

0–3

Acute phase reactants

0–1

Duration ≥6 weeks

1

Authoritative reference: Aletaha D et al. 2010 Rheumatoid Arthritis Classification Criteria. Ann Rheum Dis.https://ard.bmj.com/content/69/9/1580

Exam insight: Anti-CCP positivity carries higher weighting and predicts erosive disease.


2. Clinical Features (Most Tested Subtopic)

Articular

  • Symmetrical MCP and PIP involvement

  • Morning stiffness >60 minutes

  • Reduced grip strength

  • DIP joints typically spared

Extra-articular

  • Rheumatoid nodules

  • Interstitial lung disease

  • Vasculitis

  • Anaemia of chronic disease

  • Felty’s syndrome

Exam trap: DIP involvement suggests osteoarthritis or psoriatic arthritis—not classical RA.

3. Investigations and Imaging

Bloods

  • Raised ESR/CRP

  • Rheumatoid factor (sensitive but not specific)

  • Anti-CCP (more specific)

  • Normocytic anaemia

Imaging

  • Early: soft tissue swelling

  • Later: joint space narrowing, erosions, periarticular osteopenia

British Society for Rheumatology (BSR) guidance:https://academic.oup.com/rheumatology/article/57/6/e1/4946902

Exam pearl: Early RA may have normal X-rays.


4. DMARD Strategy (Core Pharmacology)

Conventional Synthetic DMARDs (csDMARDs)

  1. Methotrexate (first line)

  2. Sulfasalazine

  3. Leflunomide

  4. Hydroxychloroquine

Biologic DMARDs

  • TNF inhibitors (etanercept, adalimumab)

  • IL-6 inhibitors (tocilizumab)

  • Rituximab

  • Abatacept

Targeted Synthetic

  • JAK inhibitors (tofacitinib)

NICE technology appraisal guidance:https://www.nice.org.uk/guidance/ta715


5. Methotrexate – The Anchor Drug

Mechanism: Folate antagonist affecting rapidly dividing immune cells.

Key exam facts:

  • Weekly dosing (never daily)

  • Co-prescribe folic acid

  • Monitor FBC and LFTs

  • Teratogenic

  • Avoid in significant liver disease

NICE monitoring recommendations:https://www.nice.org.uk/guidance/ng100

Classic MRCP Question: A patient develops raised ALT while on methotrexate → withhold and repeat tests.


6. Biologics – Indications & Safety

Indicated when:

  • Inadequate response to ≥2 csDMARDs (including methotrexate)

  • Persistent high disease activity

Mandatory before TNF inhibitors:

  • TB screening (IGRA / chest X-ray)

  • Hepatitis screening

Exam pearl: Reactivation of latent TB is a well-tested complication.


7. Monitoring Table (Rapid Recall)

Drug

Key Risk

Monitoring

Methotrexate

Hepatotoxicity

LFTs

Sulfasalazine

Agranulocytosis

FBC

Leflunomide

Liver injury

LFTs

Hydroxychloroquine

Retinopathy

Ophthalmology review

TNF inhibitors

TB reactivation

TB screening

MRCP Part 1 candidate revising rheumatoid arthritis criteria and DMARDs using notes and question bank.

Practical Mini-Case (Exam Style)

A 38-year-old woman presents with 3 months of symmetrical MCP swelling, 2-hour morning stiffness, raised CRP and strongly positive anti-CCP. X-ray shows early erosions.

What is the most appropriate initial therapy?

A. Prednisolone aloneB. MethotrexateC. RituximabD. EtanerceptE. Ibuprofen only

Answer: B. Methotrexate

Explanation: She meets classification criteria. First-line disease-modifying therapy is methotrexate unless contraindicated. Biologics are reserved for inadequate response.

Practise similar questions in the Free MRCP MCQs or simulate exam conditions with a Start a mock test.


Five Most Tested Subtopics

  1. ACR/EULAR scoring system

  2. Anti-CCP prognostic value

  3. Methotrexate first-line status

  4. TNF inhibitor TB screening

  5. Extra-articular complications


Five Common Traps

  • Confusing RF positivity with definite RA

  • Prescribing methotrexate daily

  • Forgetting TB screening before biologics

  • Missing extra-articular lung involvement

  • Confusing RA erosions with osteophytes in OA


Practical Study-Tip Checklist

✔ Memorise scoring domains and cut-off✔ Associate each DMARD with one key toxicity✔ Revise TB screening rules✔ Compare RA vs OA in a side-by-side table✔ Practise rheumatology blocks weekly

Use the structured MRCP Part 1 overview to consolidate high-yield rheumatology systematically.

Cross-link recommendation: Integrate this topic with your broader Study plan for MRCP Part 1 to ensure spaced repetition.


FAQs (People Also Ask)

What is the first-line treatment for rheumatoid arthritis?

Methotrexate is the first-line DMARD in most patients, given weekly with folic acid and regular monitoring.

Is anti-CCP more specific than rheumatoid factor?

Yes. Anti-CCP has higher specificity and predicts more aggressive erosive disease.

When are biologics used in RA?

After failure of at least two conventional DMARDs, including methotrexate, with persistent active disease.

Which joints are typically spared in RA?

Distal interphalangeal (DIP) joints are usually spared.

Why is TB screening required before TNF inhibitors?

TNF inhibitors increase the risk of reactivating latent tuberculosis.


Ready to start?

Mastering RA requires precision and repetition. Consolidate this topic within the MRCP Part 1 overview and test yourself using our question bank today.


Sources

 
 
 

Comments

bottom of page